Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 medications like semaglutide and tirzepatide help millions manage weight and metabolic health, but questions about safety—particularly regarding blood clots—deserve clear, evidence-based answers. Research conducted across major cardiovascular outcome trials has not identified GLP-1 receptor agonists as independent risk factors for venous or arterial thrombosis in standard populations.
What Does Current Clinical Evidence Show About GLP-1 and Blood Clots?
Large-scale cardiovascular safety trials, including the LEADER trial with liraglutide and the SUSTAIN-6 trial with semaglutide, did not report increased blood clot incidence as a primary safety concern. These studies tracked thousands of participants over several years and focused on heart attacks, strokes, and cardiovascular mortality—conditions where clotting plays a central role. The absence of a signal for thrombotic events in these rigorous datasets provides substantial reassurance about GLP-1 safety in this domain.
One important distinction: some early clinical observations noted rare cases of thrombotic events in specific patient subgroups, particularly those with existing clotting disorders or recent surgeries. However, these observations remain anecdotal and have not translated into warnings in prescribing information for GLP-1 medications. PlexusDx compounded semaglutide comes from licensed 503A compounding pharmacies that follow the same safety standards as branded medications, ensuring quality and consistency.
How GLP-1 Medications Affect Blood Vessel Function and Clotting
GLP-1 receptor agonists work primarily in the pancreas and gastrointestinal tract to regulate blood sugar and appetite, but they also activate GLP-1 receptors on blood vessel walls. This activation may actually have a protective effect: GLP-1 signaling improves endothelial (inner lining) function and reduces inflammation—both factors that normally decrease clot formation rather than increase it. Weight loss itself, a primary outcome of GLP-1 therapy, is associated with improved blood flow and reduced clotting tendency.
The mechanisms that might theoretically increase clot risk—such as blood vessel injury, stasis (slow blood flow), or increased blood viscosity—are not commonly observed with GLP-1 use. In fact, improvements in blood pressure, cholesterol levels, and platelet function documented in many GLP-1 trials suggest a net reduction in thrombotic risk, especially when weight loss is achieved and sustained.
Who Should Be Most Cautious About GLP-1 and Clotting Risks?
Patients with a personal or strong family history of blood clots, inherited thrombophilias (genetic clotting disorders), or active malignancy warrant closer physician oversight before starting GLP-1 therapy. Similarly, those scheduled for major surgery should discuss timing of GLP-1 injections or oral doses with their surgical team, as any medication affecting blood vessel function deserves consideration in perioperative planning. PlexusDx recommends reviewing your complete medical history with the supervising physician before initiating treatment.
Dehydration can increase blood viscosity and clot risk independently of medication choice. GLP-1 users should maintain adequate hydration, especially during the dose-escalation phase when gastrointestinal side effects like nausea may reduce fluid intake. This simple preventive step addresses a modifiable risk factor without requiring dose adjustment or discontinuation of semaglutide or other GLP-1 compounds.
Personalized Risk Assessment With Precision Peptide Genetic Testing
PlexusDx offers the Precision Peptide Genetic Test, which examines genetic variants in pathways relevant to GLP-1 metabolism and response, including analysis of 49 peptides across 14 distinct metabolic pathways. While the test is not a pharmacogenomic thrombosis predictor, it does identify genetic predispositions in GLP-1R (rs6923761) and other peptide-signaling variants that influence how your body processes and responds to semaglutide and tirzepatide. Understanding these individual patterns helps PlexusDx physicians tailor dosing and compound selection for optimal safety and efficacy.
The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment and maps over 150 genetic insights relevant to weight loss and metabolic health. This personalized approach complements standard clinical assessment and allows your PlexusDx provider to flag any genetic risk factors that might warrant additional monitoring or alternative therapy. Combined with baseline labs and health history review, genetic insights help ensure you receive the safest, most effective GLP-1 protocol.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Does semaglutide increase the risk of blood clots?
No. Major clinical trials have not identified semaglutide as an independent cause of blood clots. Patients with existing clotting disorders or those undergoing surgery should inform their physician, but standard-risk individuals do not face elevated thrombotic risk from semaglutide therapy. PlexusDx semaglutide (starting at $149/mo) is compounded by licensed 503A pharmacies meeting FDA standards.
What clinical trials tested GLP-1 safety for blood clots?
The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) enrolled thousands of patients and measured cardiovascular outcomes including thrombotic events. Neither study reported increased clot risk as a safety signal. These trials remain the gold standard for assessing GLP-1 thrombotic safety.
Can I afford GLP-1 treatment without insurance?
Yes. PlexusDx serves all 50 states with no insurance requirement and no membership fee. Compounded semaglutide injection starts at $149/mo, and both HSA and FSA accounts are eligible. Your dose may need to go up. Your price won't.
What should I do if I have a history of blood clots?
Inform your PlexusDx provider immediately during your medical history review. Patients with prior thrombosis, thrombophilia, or cancer require individualized risk assessment and may benefit from additional monitoring or alternative therapy. Your safety is the priority.
How does the Precision Peptide Genetic Test help assess clot risk?
The test ($99 add-on after month one) analyzes 49 peptides and 150+ genetic insights including GLP1R variants and metabolic pathways relevant to your response to semaglutide. While not a clotting-disorder predictor, it identifies individual peptide-signaling patterns that help your PlexusDx physician optimize your protocol for safety and efficacy.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Help the Nausea from Ozempic and Stay on Track with Your Weight Loss Goals
Can I Take Ozempic While Breastfeeding? Navigating Weight Management and Nursing